ライフサイエンスコーパス: LPA

1 LPA 18:1 significantly regulated 20 GF novel and 27 know

2 LPA exposure leads to the loss of N-cadherin concentrati

3 LPA induces chemotaxis of remarkable accuracy, and is bo

4 LPA is a bioactive phospholipid that regulates diverse b

5 LPA is primarily derived from membrane phospholipids and

6 LPA is produced extracellularly by autotaxin (ATX), a se

7 LPA levels increase in the contused spinal cord parenchy

8 LPA signaling induced NFAT1 nuclear translocation, sugge

9 LPA signals extracellularly via cognate G protein-couple

10 LPA species with longer chain polyunsaturated acyl group

11 LPA stimulates pathways regulated by small GTPases throu

12 LPA transcriptionally induced HIF-1alpha in colon cancer

13 LPA-LPAR signaling has been implicated in development of

14 LPA-stimulated Akt/mTOR signaling is critical for LPA-me

15 LPAs have a continued role for use in settings where rap

16 the present study, mRNA expression of all 6 LPA receptor genes was detected in murine aortic VSMCs,

17 One SNP in the lipoprotein(a) (LPA) locus (rs10455872) reached genomewide significance

18 Laser-plasma accelerators (LPAs) are capable of accelerating charged particles to v

19 le in the production of lysophosphatic acid (LPA) species in blood.

20 is the lipid agonist lysophosphatidic acid (LPA) acting through the LPA receptor LPAR1.

21 LPC) to the bioactive lysophosphatidic acid (LPA) and choline.

22 s the bioactive lipid lysophosphatidic acid (LPA) and is a drug target of considerable interest for n

23 lon, and PKCzeta with lysophosphatidic acid (LPA) and their inhibition with bisindolylmaleimide I, as

24 esultant synthesis of lysophosphatidic acid (LPA) driving chemotaxis through LPA receptor 2 and actin

25 Lysophosphatidic acid (LPA) functions through activation of LPA receptors (LPAR

26 we determined that a lysophosphatidic acid (LPA) gradient induces a spatiotemporally restricted decr

27 Lysophosphatidic acid (LPA) has been recognized recently as an endothelium-depe

28 Lysophosphatidic acid (LPA) has wide-ranging effects on many different cell typ

29 of the lipid mediator lysophosphatidic acid (LPA) in biological fluids.

30 in the production of lysophosphatidic acid (LPA) in blood through hydrolysis of lysophosphatidyl cho

31 ysiological levels of lysophosphatidic acid (LPA) in blood.

32 or the lipid mediator lysophosphatidic acid (LPA) in decidualization, acting through its G-protein-co

33 ral administration of lysophosphatidic acid (LPA) increased NHE3 activity and fluid absorption in dia

34 Lysophosphatidic acid (LPA) is a bioactive phospholipid that is present in all

35 Lysophosphatidic acid (LPA) is a growth factor-like mediator and a ligand for m

36 Lysophosphatidic acid (LPA) is a major lysophospholipid found systemically, and

37 Lysophosphatidic acid (LPA) is a natural bioactive lipid that acts through six

38 Lysophosphatidic acid (LPA) is a pleiotropic lipid molecule with potent effects

39 Lysophosphatidic acid (LPA) is an extracellular lipid mediator involved in many

40 Lysophosphatidic acid (LPA) is an important bioactive lipid species that is par

41 Lysophosphatidic acid (LPA) is an important mediator of pulmonary fibrosis.

42 small bioactive lipid lysophosphatidic acid (LPA) plays critical roles in both normal physiology and

43 by activation of the lysophosphatidic acid (LPA) receptor (LPAR) via SRC-dependent transactivation o

44 ously, we showed that lysophosphatidic acid (LPA) receptor 1 regulates proliferation of intestinal ep

45 adherin downstream of lysophosphatidic acid (LPA) receptor 2.

46 t the bioactive lipid lysophosphatidic acid (LPA) regulates hepatocyte glucose production by antagoni

47 The lipid mediator lysophosphatidic acid (LPA) signals via six distinct G protein-coupled receptor

48 Lysophosphatidic acid (LPA) stimulates the formation of stabilized detyrosinate

49 ctivation of YAP upon lysophosphatidic acid (LPA) stimulation and the inhibition of YAP-induced cell

50 tidylcholine (LPC) or lysophosphatidic acid (LPA) to cells restored their oxidant generation.

51 Lysophosphatidic acid (LPA), a growth factor-like phospholipid, regulates numer

52 Lysophosphatidic acid (LPA), a lipid by-product of autotaxin activity, is invol

53 zes the production of lysophosphatidic acid (LPA), a pleiotropic growth-factor-like lysophospholipid.

54 Lysophosphatidic acid (LPA), a potent bioactive lipid found in atherosclerotic

55 indings indicate that lysophosphatidic acid (LPA), a potent neuronal activator, and autotaxin (ATX; e

56 Here, we show that lysophosphatidic acid (LPA), a signaling molecule derived from PC, regulated he

57 Lysophosphatidic acid (LPA), an endogenous lipid widely associated with neuropa

58 y signal initiated by lysophosphatidic acid (LPA), an upstream regulator of Yap that can cause fetal

59 T1), autotaxin (ATX), lysophosphatidic acid (LPA), and beta-catenin that contributes to progression o

60 ts enzymatic product, lysophosphatidic acid (LPA), are elevated during HCV infection, and LPA activat

61 a the signaling lipid lysophosphatidic acid (LPA), linking it with GPAM to cell migration.

62 t the bioactive lipid lysophosphatidic acid (LPA), prevalent in the EOC microenvironment, functions t

63 al sensitivity toward lysophosphatidic acid (LPA), which failed to repel PRG-2-deficient thalamocorti

64 edge is epitomized by lysophosphatidic acid (LPA), which functions through interactions with at least

65 p27(KIP1) to enhance lysophosphatidic acid (LPA)-induced ovarian cancer cell migration.

66 hosphatidylcholine to lysophosphatidic acid (LPA).

67 ression was driven by lysophosphatidic acid (LPA).

68 id signaling molecule lysophosphatidic acid (LPA).

69 nse to treatment with lysophosphatidic acid (LPA).

70 es the lipid mediator lysophosphatidic acid (LPA).

71 tor agonists, notably lysophosphatidic acid (LPA; acting through the LPA1 receptor) and endothelin.

72 well as some of the lysophosphatidic acids (LPA) in the small intestine were also increased in respo

73 oline (LPC 18:1) and lysophosphatidic acids (LPAs) in the intestine and plasma.

74 a (INV), lepidic-predominant adenocarcinoma (LPA), and adenocarcinoma in situ (AIS)/minimally invasiv

75 INF2 localized to MTs after LPA treatment in an mDia1-dependent manner, suggesting t

76 ned myosin light chain phosphorylation after LPA stimulation.

77 formation of leukocyte-platelet aggregates (LPA) that facilitated leukocyte infiltration to the affe

78 ion and upregulation of LIPH, an alternative LPA-producing enzyme, suggesting that this gene could fu

79 Recent data implicate an LPA genetic variant (rs10455872), associated with Lp(a)

80 , further suggesting that CD97 influences an LPA-associated mechanism of progression.

81 A-induced FAK activation, indicating that an LPA-Cyr61-FAK axis leads to SMC migration.

82 The latent profile analysis (LPA), with data of seven in vitro methods and one assay

83 TNF-alpha and LPA also led to sustained p42/44 MAPK phosphorylation an

84 l proresolving network centered on ANXA1 and LPA generation and identify previously unappreciated det

85 viously described associations with APOE and LPA.

86 mice demonstrated enhanced, constitutive and LPA-stimulated ERK activation.

87 rs identify associations at HLA-DQA/DRB1 and LPA and find that genetic variants that increase educati

88 associated with longevity (HLA-DQA1/DRB1 and LPA).

89 We show that VEGF-A, histamine, IGFBP3, and LPA trigger unequal endothelial responses when acting fr

90 LPA), are elevated during HCV infection, and LPA activates immunocytes, but whether this contributes

91 bstrate-product relationship between LPC and LPA in pulmonary fibrosis.

92 elated with IL-6, sCD14, sCD163, Mac2BP, and LPA levels in HCV-infected participants and with Mac2BP

93 ated increase in HETEs, HODEs, AA, PGD2, and LPA.

94 was dependent on autocrine ATX secretion and LPA signaling.

95 taneously harbouring TUDCA in the tunnel and LPA in the pocket, together with kinetic analysis, revea

96 tudies have established that Erk antagonizes LPA-mediated regression, we considered whether Erk was a

97 Here, we engineer the Light Plate Apparatus (LPA), a device that can deliver two independent 310 to 1

98 nce GmbH, Nehren, Germany) line probe assay (LPA) encountered during a feasibility and validation stu

99 ted performance data from line probe assays (LPAs), nucleic acid tests used for the rapid diagnosis o

100 a confirms that our lead compound attenuates LPA mediated signaling in cells and reduces LPA synthesi

101 itive inhibitors of ATX, thereby attenuating LPA receptor activation.

102 ATX-LPA receptor signaling is essential for normal developme

103 ATX-LPA signalling is involved in multiple biological and pa

104 The autotaxin-lysophophatidic acid (ATX-LPA) signaling pathway is implicated in a variety of hum

105 Thus, together, our data suggest that an ATX-LPA-HDAC1/2 axis regulates OLG differentiation specifica

106 This unexpected interplay between ATX-LPA signalling and select steroids, notably natural bile

107 s revealed that the regulatory effect of ATX-LPA signaling was mediated by PI3K/Akt-Smad pathway.

108 As a result, ATX-LPA has become of significant interest within both the i

109 Our results indicate that ATX-LPA-LPA3 signaling at the embryo-epithelial boundary ind

110 The ATX-LPA pathway has been implicated in many pathologic condi

111 The ATX-LPA signaling axis arouses a high interest in the drug d

112 The ATX-LPA signaling pathway is implicated in cell survival, mi

113 established a liver profibrotic role for ATX/LPA, whereas pharmacological ATX inhibition studies sugg

114 noma (HCC) development, thus implicating ATX/LPA in the causative link of cirrhosis and HCC.

115 le, we review current thinking about the ATX/LPA axis in lymphocyte homing, as well as in models of a

116 ear translocation, suggesting that autocrine LPA synthesis promotes NFAT1 transcriptional activation

117 Autotaxin, LPA, and sCD14 levels normalized, while sCD163 and Mac2B

118 A role for the autotaxin/LPA axis has been suggested in many disease areas includ

119 Interestingly, knockdown of Cyr61 blocked LPA-induced FAK activation, indicating that an LPA-Cyr61

120 Both LPA assays performed well in specimens from HIV-infected

121 vo Cyr61 in the extracellular matrix bridges LPA and integrin pathways, which in turn, activate FAK,

122 regulating cell migration, was activated by LPA at a late time frame coinciding with Cyr61 accumulat

123 educed acute stimulation of NHE3 activity by LPA/LPA5R stimulation; and 3) reduced acute inhibition o

124 interaction of mDia1 and INF2 was induced by LPA and dependent on IQGAP1.

125 icellular protein Cyr61 is highly induced by LPA.

126 bility of a tripartite complex stimulated by LPA.

127 The di-C18 LPAs share the ability of burying their lipid chains in

128 e demonstrate for the first time that di-C18 LPAs trigger pro-inflammatory responses through Toll-lik

129 a secretory lysophospholipase that catalyzes LPA production, inhibited hematopoietic differentiation

130 f regulated interactions between circulating LPA, ATX, and platelets remain undefined in cancer.

131 ated lipoprotein(a) levels and corresponding LPA risk genotypes (rs10455872, rs3798220, kringle IV ty

132 treme lipoprotein(a) levels or corresponding LPA KIV-2/rs10455872 risk genotypes substantially improv

133 his study, we identify the G-protein-coupled LPA receptor 2 (LPAR2) as a signal transducer specifical

134 GTPases through binding to G-protein-coupled LPA receptors (LPARs).

135 CD97 depletion reduced RHO-GTP and decreased LPA-stimulated invasion but not EGF-stimulated invasion,

136 pectrometry was used to assay time-dependent LPA species production by GFs.

137 lockade and siRNA inhibition both diminished LPA-induced SMC migration, indicating a novel regulatory

138 sasii, half of which were detected by Direct LPA.

139 e MTBDRplus (MTBDR-Plus) and GenoType Direct LPA (Direct LPA) was compared to a gold standard of one

140 (MTBDR-Plus) and GenoType Direct LPA (Direct LPA) was compared to a gold standard of one mycobacteria

141 tuberculosis identification with the Direct LPA and 44.1% sensitivity with MTBDR-Plus.

142 The Direct LPA had a sensitivity of 88.4% and a specificity of 94.6

143 ent had 1 sputum specimen tested with Direct LPA, MTBDR-Plus LPA, smear microscopy, MGIT, biochemical

144 Cells rapidly break down LPA present at substantial levels in culture medium and

145 tration in plasma 0.95, 0.81-1.11 and either LPA SNP 1.10, 0.92-1.31) or cardiovascular mortality (0.

146 ial infarction per 1-SD difference in either LPA KIV2 repeats or lipoprotein(a) concentration.

147 95% CI 1.14-1.83) and the presence of either LPA SNP (1.88, 1.40-2.53).

148 (PLPP1) had a 2-fold increase in endogenous LPA levels, reduced PEPCK levels during fasting, and dec

149 ther the tumour growing to break down enough LPA to form a gradient.

150 atment of primary hepatocytes with exogenous LPA blunted glucagon-induced PEPCK expression and glucos

151 ancer cell motility, generates extracellular LPA from the precursor lysophosphatidylcholine.

152 e involved in the synthesis of extracellular LPA.

153 Stable electron beams from a first LPA were focused to a twenty-micrometre radius--by a dis

154 human salivary and gingival crevicular fluid LPA species, 18:1, and that they would express transcrip

155 er than the 14.5% (95% CI: 10.3%, 18.7%) for LPA (P = .002).

156 otein(a) concentration, after adjustment for LPA KIV2 repeats and conventional lipids.

157 timulated Akt/mTOR signaling is critical for LPA-mediated macrophage development in mice.

158 lternative enzymatic pathways also exist for LPA production.

159 Our study demonstrates a role for LPA in early forebrain development.

160 These findings identify a critical role for LPA in regulating innate immune system.

161 1 antagonist, confirming an in vivo role for LPA signaling in beta-catenin activation.

162 had a trend toward being lower than that for LPA (P = .051).

163 phosphodiesterase 2), the enzyme which forms LPA, may form a key element of the long-sought pruritoge

164 SMCs derived from LPA receptor 1 (LPA1) knock-out mice lack the ability of

165 probe morphological changes that result from LPA treatment.

166 Furthermore, LPA treatment initiates nuclear translocation of beta-ca

167 el risk locus was identified within the gene LPA (rs12207195; posterior probability 0.925) after rewe

168 low-frequency missense variants in the genes LPA and PCSK9.

169 Similarly, orally given LPA blocked tumor necrosis factor-mediated intestinal ba

170 ditions relevant to epidermal wound healing, LPA induces SOCE and NFAT activation through Orai1 chann

171 novel role for PLPP1 activity and hepatocyte LPA levels in glucagon sensitivity via a mechanism invol

172 To better understand how LPA and other lipid analogs might interact and affect th

173 In humans, LPA mediates macrophage formation following similar path

174 Taken together, we identified LPA as an important nutrient-derived developmental cue f

175 These results implicate LPA exerting actions on GFs that are compatible with fun

176 Importantly, LPA did not blunt glucagon-stimulated glucose production

177 ured copy numbers of kringle IV-2 (KIV-2) in LPA using qPCR.

178 une function and suggest that alterations in LPA levels likely influence adaptive humoral immunity.

179 I 0.90-0.97; p<0.0001) per 1-SD increment in LPA KIV2 repeats after adjustment for lipoprotein(a) con

180 t, PPARgamma was not found to be involved in LPA-mediated effects.

181 The rs10455872 genetic variant in LPA was genotyped in 14 735 study participants, who simu

182 atocyte ATX expression, leading to increased LPA levels, activation of hepatic stellate cells (HSCs),

183 ution of LPA in the spinal cord, we injected LPA into the normal spinal cord, revealing that LPA indu

184 dings show how GPAM influences intracellular LPA levels to promote cell migration and tumor growth.

185 radixin accumulation in growth cones and its LPA-dependent phosphorylation depend on its binding to s

186 Lipopolyamines (LPAs) are cationic lipids; they interact spontaneously w

187 they would express transcript for the major LPA-producing enzyme autotaxin.

188 We measure LPA gradients across the margins of melanomas in vivo, c

189 Mechanistically, LPA antagonized glucagon-mediated inhibition of STAT3, a

190 We hypothesized that Cyr61 mediates LPA-induced cell migration.

191 Performance of the MTBDRsl LPA might be improved by replacing the gyrA wild-type pr

192 sent, and GFs were found to produce multiple LPA species in a time-dependent manner.

193 Among the natural LPA analogs, we found that only LPA 18:1, alkylglyceroph

194 The pharmacological activation of LPA receptor subtypes represent a novel strategies for a

195 c acid (LPA) functions through activation of LPA receptors (LPARs).

196 ion of LPC for conversion to LPA; binding of LPA to LPAR1 signals rac activation.

197 Pharmacological and genetic blockage of LPA receptor 1 (LPAR1) or autotoxin (ATX), a secretory l

198 To model this potential contribution of LPA in the spinal cord, we injected LPA into the normal

199 nscriptional regulator in the development of LPA-induced macrophages.

200 view the developmentally related features of LPA signalling.

201 Here, we reveal an unexpected function of LPA that transfigures CD11b(+) murine monocytes into F4/

202 proach to further elucidate the functions of LPA receptors during red blood cell (RBC) differentiatio

203 e likely responsible for local generation of LPA in the injured lung.

204 er, little is known about the involvement of LPA in CNS pathologies.

205 determined for the first time that levels of LPA mRNA were higher in the carriers than non-carriers o

206 Therefore, understanding the mechanism of LPA-induced SMC migration is important.

207 ecent years in deciphering the mechanisms of LPA generation and how it acts on target cells.

208 rally restricted decrease in the mobility of LPA receptor 2 (LPA2) on chemotactic fibroblasts.

209 drives cell dispersal is not the presence of LPA itself, but the self-generated, outward-directed gra

210 et aggregation, leading to the production of LPA.

211 A wide range of LPA effects have been identified in the CNS, including n

212 1 was able to cause a sustained reduction of LPA levels in plasma in vivo and was shown to be efficac

213 m, with particular focus on the relevance of LPA to both physiological and diseased states.

214 New insights into the role of LPA in regulating immune responses should be forthcoming

215 However, the role of LPA-LPAR signaling in development of diabetic nephropath

216 rease in lipid composition on the surface of LPA-treated cells.

217 his Review covers a current understanding of LPA signaling in the nervous system, with particular foc

218 and abdominal aorta (AA) segments, 1-oleoyl-LPA and the LPA1-3 agonist VPC31143 induced dose-depende

219 the natural LPA analogs, we found that only LPA 18:1, alkylglycerophosphate 18:1, and cyclic phospha

220 Whether lipoprotein(a) concentrations or LPA genetic variants predict long-term mortality in pati

221 Of these, 9 SNPs were near the PLG or LPA genes on Chr6q26, whereas 2 were on Chr19q13 and 5'

222 isted longer than in the presence of VEGF or LPA alone.

223 In particular, LPA signalling has been shown to affect fertility and re

224 ound 40 was also able to decrease the plasma LPA levels upon oral administration to rats.

225 specimen tested with Direct LPA, MTBDR-Plus LPA, smear microscopy, MGIT, biochemical identification

226 an that of commercial linear polyacrylamide (LPA)-coated capillaries.

227 ing as a sink, breaking down locally present LPA, and thus forming a gradient that is low in the tumo

228 and multiple tumor types, autotaxin produces LPA from lysophosphatidylcholine (LPC) via lysophospholi

229 ned the role of autotaxin (ATX) in pulmonary LPA production during fibrogenesis in a bleomycin mouse

230 and in the lung, without effect on pulmonary LPA or fibrosis.

231 LPA mediated signaling in cells and reduces LPA synthesis in vivo, providing a promising natural pro

232 x deposition in the lung while also reducing LPA 18:2 content in bronchoalveolar lavage fluid.

233 ur findings strengthen the argument for safe LPA-targeted intervention to reduce cardiovascular risk.

234 demonstrates that potentially any saturated LPA currently used or proposed as transfection agent is

235 lary-based active plasma lens--into a second LPA, such that the beams interacted with the wakefield e

236 elucidate variation within LPA, we sequenced LPA and identified two variants most strongly associated

237 However, the energy gain in a single-stage LPA can be limited by laser diffraction, dephasing, elec

238 nce of NHE3 in diabetic diarrhea and suggest LPA administration as a potential therapeutic strategy f

239 Overall, these results support LPA-LPA1 signaling as a novel pathway that contributes t

240 ire identification to therapeutically target LPA production in pulmonary fibrosis.

241 We conclude that LPA chemotaxis provides a strong drive for melanoma cell

242 Our results demonstrate that LPA induces loss of junctional beta-catenin, stimulates

243 a previous study, we have demonstrated that LPA activates erythropoiesis by activating the LPA 3 rec

244 We have previously demonstrated that LPA is necessary for successful in vitro osteoclastogene

245 We also determined that LPA activation of a PKCalpha-mediated signaling pathway

246 We found that LPA increased expression of PKCalpha and PKCzeta only, w

247 Our findings indicate that LPA causes vasoconstriction in VSMCs, mediated by LPA1-,

248 disciplines, but emerging data indicate that LPA has an important role to play in immunity.

249 into the normal spinal cord, revealing that LPA induces microglia/macrophage activation and demyelin

250 This study reveals that LPA signaling via LPA receptor type 1 activation causes

251 Using FRET-based biosensors, we show that LPA and endothelin transiently activate Cdc42 through Gi

252 Our data show that LPA induced temporal and spatial expression of Cyr61, wh

253 a transactivator of HIF-1alpha and show that LPA regulates HIF-1alpha by dynamically modulating its i

254 ry (IL-11) ILs, along with SOCS2, shows that LPA transiently regulates a complex set of GF genes crit

255 Together these data suggest that LPA initiates EMT in ovarian tumors through beta1-integr

256 rein, we demonstrate for the first time that LPA signaling via LPA1 contributes to secondary damage a

257 The LPA dramatically reduces the entry barrier to optogeneti

258 The LPA locus link with cardiovascular risk exemplifies how

259 A activates erythropoiesis by activating the LPA 3 receptor subtype (LPA3) under erythropoietin (EPO)

260 that this new-found interaction between the LPA/LPA1 and TXA2/TP pathways plays significant roles in

261 However, the LPA and LPC species that increase in BAL of bleomycin-in

262 hod (kringle IV type 2 [KIV2] repeats in the LPA gene) and a serum-based electrophoretic assay in pat

263 has suggested that a genetic variant in the LPA region was associated with the presence of aortic va

264 pproximately 5.3 Mb region that included the LPA gene.

265 Similarly, knockout mice lacking the LPA-degrading enzyme phospholipid phosphate phosphatase

266 g transplant model of BOS, antagonism of the LPA receptor (LPA1) or ATX inhibition decreased allograf

267 Knockout of Lpar3 or inhibition of the LPA-producing enzyme autotaxin (ATX) in pregnant mice le

268 sophosphatidic acid (LPA) acting through the LPA receptor LPAR1.

269 alpha6beta1 and alphanubeta3 transduced the LPA-Cyr61 signal toward FAK activation and migration.

270 We use the LPA to precisely control gene expression from blue, gree

271 Therefore, LPA may potentially modulate/regulate periodontal inflam

272 These LPA-influenced processes impact many aspects of organism

273 n length, saturation, and headgroup of these LPA analogs, we established strict requirements for acti

274 atidic acid (LPA) driving chemotaxis through LPA receptor 2 and actin cytoskeletal mobilization.

275 xis themselves, but potentiate chemotaxis to LPA.

276 a new mechanism for platelet contribution to LPA-dependent metastasis of breast cancer cells, and dem

277 through generation of LPC for conversion to LPA; binding of LPA to LPAR1 signals rac activation.

278 on by generation of LPC that is converted to LPA by the lysophospholipase D activity of autotaxin (AT

279 l cell indicating a differential response to LPA treatment with cancer progression.

280 ing and directional migration in response to LPA.

281 directional migration of fibroblasts toward LPA.

282 Two LPA stages were coupled over a short distance (as is nee

283 poprotein(a) concentration in plasma and two LPA single-nucleotide polymorphisms ([SNPs] rs10455872 a

284 In total, 28 patients underwent LPA reanastomosis and/or tracheoplasty in our center, an

285 TLR1 and TLR6-driven heterodimerization upon LPA binding underlines the highly collaborative and prom

286 n by mature murine B cells is inhibited upon LPA engagement of the LPA5 (GPR92) receptor via a Galpha

287 e separation conditions were optimized using LPA-co-dihexylacrylamide block copolymers specifically d

288 This study reveals that LPA signaling via LPA receptor type 1 activation causes demyelination and

289 In vitro, LPA activated monocytes.

290 restricted ligand specificity compared with LPA G-protein-coupled receptors.

291 ility, which was blocked by cotreatment with LPA, but not LPA1 knockdown cells.

292 gnals from cellular sheddings from MCAs with LPA treatment are consistent with cleavage of proteins o

293 t ATX have been crystallized previously with LPA or small-molecule inhibitors bound.

294 fiber formation, following stimulation with LPA as well as p21-activated kinase (PAK)-mediated lamel

295 multiple types of cancers, and together with LPA generated during platelet activation promotes skelet

296 regates (MCAs) are removed by treatment with LPA.

297 microvilli-like features upon treatment with LPA.

298 cal and chemical responses to treatment with LPA.

299 To further elucidate variation within LPA, we sequenced LPA and identified two variants most s

300 , during in vivo embryogenesis in zebrafish, LPA functioned as a developmental cue for hemangioblast